BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?

BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Brian Mueller - Executive Vice President and Chief Financial Officer Cristin Hubbard - Executive Vice President and Chief Commercial Officer Greg Friberg - Executive Vice President and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen Salveen Richter - Goldman Sachs Jessica Fye - JPMorgan Paul Matteis - Stifel Eli Merle - UBS Cory Kasimov - Evercore Kostas Biliouris - BMO Capital Markets Joseph Schwartz - Leerink Partners Akash Tewari - Jefferies Christopher Raymond - Piper Sandler Mohit Bansal - Wells Fargo John Wang - Barclays Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago.

Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y) During the Quarter, Strong Demand Drove 54% Y/Y Revenue Growth for VOXZOGO® During the Quarter, Revenues from Enzyme Therapies Portfolio Increased 27% Y/Y Third Quarter 2024 GAAP Diluted Earnings Per Share (EPS) of $0.55 (+162% Y/Y); Year-to-date 2024 GAAP Diluted EPS of $1.56 (+103% Y/Y) Third Quarter 2024 Non-GAAP Diluted EPS of $0.91 (+98% Y/Y); Year-to-date 2024 Non-GAAP Diluted EPS of $2.60 (+63% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.